Key facts
- AstraZeneca announced positive results for Imfinzi + Imjudo in liver cancer.
- The combination therapy showed significant survival benefits in patients with unresectable hepatocellular carcinoma.
AstraZeneca's Imfinzi and Imjudo combination therapy has demonstrated positive outcomes in clinical trials for liver cancer. This development is significant for patients with unresectable hepatocellular carcinoma, offering potential for improved survival rates.